DK1218494T3 - Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler - Google Patents

Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler

Info

Publication number
DK1218494T3
DK1218494T3 DK00964563T DK00964563T DK1218494T3 DK 1218494 T3 DK1218494 T3 DK 1218494T3 DK 00964563 T DK00964563 T DK 00964563T DK 00964563 T DK00964563 T DK 00964563T DK 1218494 T3 DK1218494 T3 DK 1218494T3
Authority
DK
Denmark
Prior art keywords
methods
inhibiting
cells
cell cycle
dna damaging
Prior art date
Application number
DK00964563T
Other languages
Danish (da)
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of DK1218494T3 publication Critical patent/DK1218494T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00964563T 1999-09-22 2000-09-21 Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler DK1218494T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (1)

Publication Number Publication Date
DK1218494T3 true DK1218494T3 (da) 2005-08-08

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00964563T DK1218494T3 (da) 1999-09-22 2000-09-21 Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003052483A1 (fr) 2001-12-17 2003-06-26 Olympus Corporation Systeme de microscope
ES2311703T3 (es) * 2002-01-17 2009-02-16 Takeda Pharmaceutical Company Limited Peptidos y peptidomimeticos que tienen actividad anti-proliferativa y/o que aumentan agentes o tratamientos que dañan los acidos nucleicos.
ES2329778T3 (es) 2002-01-18 2009-12-01 Novozymes A/S 2,3-aminomutasa de alanina.
JP4919598B2 (ja) 2002-06-06 2012-04-18 株式会社 キャンバス Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物
AU2004203977B2 (en) 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
WO2004093873A1 (en) 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
CA2530900A1 (en) 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
MXPA06003110A (es) * 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.
US7250427B2 (en) 2004-06-30 2007-07-31 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers
CN105175394B (zh) 2007-04-11 2018-06-08 三井有限公司 具有抗癌活性的化合物
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
CN102149725A (zh) * 2008-05-14 2011-08-10 三井有限公司 用于抑制g2细胞周期停滞和使细胞对dna损伤剂敏感的cbp501衍生制剂及基于其的方法
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2017143397A1 (en) * 2016-02-23 2017-08-31 Monash University INHIBITORS OF β-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN
CN114470178A (zh) * 2019-12-05 2022-05-13 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
AU6014998A (en) * 1997-01-13 1998-08-03 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
CA2385257A1 (en) 2001-03-29
JP2003518368A (ja) 2003-06-10
US6881575B1 (en) 2005-04-19
EP1218494B1 (de) 2005-04-06
ATE292677T1 (de) 2005-04-15
ES2239037T3 (es) 2005-09-16
US7851592B2 (en) 2010-12-14
PT1218494E (pt) 2005-08-31
DE60019318T2 (de) 2006-03-09
JP4610828B2 (ja) 2011-01-12
WO2001021771A2 (en) 2001-03-29
EP1218494A2 (de) 2002-07-03
US20050059116A1 (en) 2005-03-17
AU7548500A (en) 2001-04-24
DE60019318D1 (de) 2005-05-12
WO2001021771A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DK1218494T3 (da) Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20005448D0 (no) Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert pÕ patologisk celleproliferering
NO20061194L (no) Mitotiske kinesininbibitorer
BR0313396A (pt) 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TR200002446T2 (tr) Fosfolipaz enzimlerinin inhibitörleri
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20052928L (no) Nye kjemiske forbindelser
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BR0208373A (pt) Inibidores da tirosina cinase
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
TR200001174T2 (tr) Protein tirozin kinaz ve protein serin/treonin kinaz inhibitörleri olarak ikameli oksindol türevleri
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO20032759L (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som Cds1/Chk2-inhibitorerog adjuvanter for kjemoterapi eller strålingsterapi ved behandlingav cancer
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE434614T1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
NO20073113L (no) Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung